Altamira Reaches COVAMID Trial Enrollment Midpoint for Bentrio in Acute COVID-19
Altamira Therapeutics (NASDAQ:CYTO) announced reaching the enrollment midpoint in its COVAMID trial of Bentrio nasal spray for acute COVID-19. The trial aims to evaluate Bentrio's effectiveness in reducing SARS-CoV-2 viral load, alleviating symptoms, and decreasing hospital admissions. A total of 136 COVID-19 patients will participate in a randomized study. Positive in vitro results have already been observed, with plans to expand the trial to North Macedonia and possibly India. Completion is anticipated by Q3 2022.
- Reached midpoint enrollment in COVAMID trial for Bentrio nasal spray.
- In vitro studies show Bentrio reduces viral load by over 99%.
- Plans to expand the trial geographically to North Macedonia and India.
- No financial metrics or timelines provided for trial completion.
- Dependence on COVID-19 incidence rates for trial expansion.
HAMILTON, BERMUDA / ACCESSWIRE / April 19, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that that it has reached the midpoint for enrollment in its COVAMID clinical investigation of its Bentrio™ nasal spray in patients with acute COVID-19.
COVAMID is a randomized, placebo controlled clinical trial to evaluate the ability of Bentrio nasal spray to reduce the SARS-CoV-2 viral load in the nose, alleviate COVID-19 signs and symptoms, and decrease the frequency of COVID-19 related hospital admissions. In the COVAMID trial, 136 confirmed (via a positive PCR test) COVID-19 patients will be randomized at a 2:1:1 ratio to receive for 10 days either Bentrio, a placebo (Bentrio minus its key mineral component), or no treatment, followed by a 10-day observation phase. Depending on the outcomes from a pre-specified blinded interim analysis, the number of participants may be increased to a maximum of 180 COVID-19 patients. The COVAMID study began in Bulgaria in early March 2022.
"We are pleased to have reached this important interim milestone in the COVAMID trial," commented Thomas Meyer, Altamira Therapeutics' founder, Chairman and CEO. "Clinically, we have already demonstrated the protective effects of Bentrio against airborne allergens. With COVAMID, we expect similar results for airborne viruses, which will be essential for the broader marketing of Bentrio as a viral infection therapeutic. So far, multiple in vitro studies with Bentrio on human nasal epithelia cells have demonstrated a significant reduction of the viral titer with either prophylactic or therapeutic applications."
The Company plans to extend the COVAMID trial to North Macedonia, which borders Bulgaria to the west, and possibly also to India. Subject to sufficient COVID-19 incidence rates in the study countries, the Company expects to complete the study during the third quarter of 2022.
About Bentrio™
Bentrio (AM-301) is a drug-free nasal spray intended for personal protection against airborne viruses and allergens. Upon application into the nose, Bentrio forms a protective gel layer on the nasal mucosa. This thin film is designed to prevent the contact of viruses or allergens with cells; in addition, the composition serves to bind such particles and help with their discharge and to humidify the nasal mucosa. Together, this is designed to reduce the risk of upper respiratory tract viral infections and promote alleviation of allergic symptoms. In human nasal epithelium cells infected by SARS-CoV-2, Bentrio was shown to reduce the infectious viral load by more than
About Altamira Therapeutics
Altamira Therapeutics (NASDAQ:CYTO) is dedicated to developing therapeutics that address important unmet medical needs. The Company is currently active in three areas: the development of RNA therapeutics for extrahepatic therapeutic targets (OligoPhore™ / SemaPhore™ platforms; preclinical), nasal sprays for protection against airborne viruses and allergens (Bentrio; commercial) or the treatment of vertigo (AM-125; Phase 2), and the development of therapeutics for intratympanic treatment of tinnitus or hearing loss (Keyzilen® and Sonsuvi®, Phase 3). Founded in 2003, it is headquartered in Hamilton, Bermuda, with its main operations in Basel, Switzerland. For more information, visit: https://altamiratherapeutics.com.
Forward-looking Statements
This press release may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Altamira Therapeutics' strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may", "might", "will", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "projects", "potential", "outlook" or "continue", or the negative of these terms or other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the approval, timing of commercialization and commercial success of AM-301, Altamira Therapeutics' need for and ability to raise substantial additional funding to continue the development of its product candidates, the timing and conduct of clinical trials of Altamira Therapeutics' product candidates, the clinical utility of Altamira Therapeutics' product candidates, the timing or likelihood of regulatory filings and approvals, Altamira Therapeutics' intellectual property position and Altamira Therapeutics' financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Altamira Therapeutics' capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Altamira Therapeutics' Annual Report on Form 20-F for the year ended December 31, 2021, and in Altamira Therapeutics' other filings with the SEC, which are available free of charge on the Securities Exchange Commission's website at: www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Altamira Therapeutics or to persons acting on behalf of Altamira Therapeutics are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Altamira Therapeutics does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law.
Investor contact:
Investors@altamiratherapeutics.com
800-460-0183
SOURCE: Altamira Therapeutics
View source version on accesswire.com:
https://www.accesswire.com/697853/Altamira-Reaches-COVAMID-Trial-Enrollment-Midpoint-for-Bentrio-in-Acute-COVID-19
FAQ
What is the COVAMID trial related to Altamira Therapeutics?
What is Bentrio's role in the COVAMID trial?
When did the COVAMID trial begin?
What were the outcomes measured in the COVAMID trial?
What is the expected completion date for the COVAMID trial?
